New Drug Applications

Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application

6 years ago
by David Miller
954 Views
Written by David Miller

INDIANAPOLIS, Jan. 29, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for selpercatinib…Original Article

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts
[mwai_chat window="true" fullscreen="true"]